The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.

This study was designed to determine the effects of vandetanib, a small-molecule receptor tyrosine kinase inhibitor of vascular endothelial growth factor and epidermal growth factor receptor, on paclitaxel (PTX) tumor distribution and antitumor activity in xenograft models of human ovarian carcinoma...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Cesca, M, Frapolli, R, Berndt, A, Scarlato, V, Richter, P, Kosmehl, H, D'Incalci, M, Ryan, A, Giavazzi, R
Natura:	Journal article
Lingua:	English
Pubblicazione:	2009

Documenti analoghi

The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma
di: Marta Cesca, et al.
Pubblicazione: (2009-11-01)

Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts
di: Edmond Auzenne, et al.
Pubblicazione: (2007-06-01)

Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
di: Wachsberger, P, et al.
Pubblicazione: (2009)

Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging.
di: Lavinia Morosi, et al.
Pubblicazione: (2013-01-01)

Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
di: Choi, S, et al.
Pubblicazione: (2008)

Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts
di: Demuytere J, et al.
Pubblicazione: (2024-01-01)

Modulation of gene expression associated with copy number variation identifies key regulatory programs in high-grade serous ovarian carcinoma
di: Martina Vescio, et al.
Pubblicazione: (2023-07-01)

Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma
di: Hideki Iwamoto, et al.
Pubblicazione: (2011-03-01)

The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.
di: Cervellini, I, et al.
Pubblicazione: (2010)

Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
di: Tai, J, et al.
Pubblicazione: (2010)

Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat
di: Tai, J, et al.
Pubblicazione: (2010)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
di: Nils Degrauwe, et al.
Pubblicazione: (2012-06-01)

Biodistribution and pharmacokinetics of a telodendrimer micellar paclitaxel nanoformulation in a mouse xenograft model of ovarian cancer
di: Xiao W, et al.
Pubblicazione: (2012-03-01)

Selective use of vandetanib in the treatment of thyroid cancer
di: Fallahi P, et al.
Pubblicazione: (2015-07-01)

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models
di: Lavinia Morosi, et al.
Pubblicazione: (2021-09-01)

Assessment of Acute Antivascular Effects of Vandetanib with High-Resolution Dynamic Contrast-Enhanced Computed Tomographic Imaging in a Human Colon Tumor Xenograft Model in the Nude Rat
di: Joo Ho Tai, et al.
Pubblicazione: (2010-09-01)

Biophysical and computational characterization of vandetanib–lysozyme interaction
di: Kabir, Md Zahirul, et al.
Pubblicazione: (2018)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
di: Abdul Qadir, MPhil, et al.
Pubblicazione: (2023-10-01)

Dermoscopic findings of perifollicular pigmentation associated with vandetanib
di: Jade Cury-Martins, et al.
Pubblicazione: (2018-10-01)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
di: Roberta Affatato, et al.
Pubblicazione: (2022-05-01)

A novel compound ARN-3236 inhibits salt-inducible kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
di: Zhou, J, et al.
Pubblicazione: (2016)

Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
di: Alferez, D, et al.
Pubblicazione: (2010)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
di: Francesca Ricci, et al.
Pubblicazione: (2017-05-01)

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC
di: Heymach, J, et al.
Pubblicazione: (2008)

Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
di: Siemann, D, et al.
Pubblicazione: (2009)

Inhibitory effect of luteolin on the metabolism of vandetanib in vivo and in vitro
di: Yuxin Shen, et al.
Pubblicazione: (2025-03-01)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
di: Hari Deshpande, et al.
Pubblicazione: (2011-01-01)

Clusterin Interacts with Paclitaxel and Confer Paclitaxel Resistance in Ovarian Cancer
di: Dong Choon Park, et al.
Pubblicazione: (2008-09-01)

Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma
di: Ai Matsui, et al.
Pubblicazione: (2022-01-01)

Establishment and characterization of ovarian clear cell carcinoma patient-derived xenografts
di: Joseph J. Caumanns, et al.
Pubblicazione: (2025-02-01)

Driving p53 Response to Bax Activation Greatly Enhances Sensitivity to Taxol by Inducing Massive Apoptosis
di: Paola De Feudis, et al.
Pubblicazione: (2000-05-01)

Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts.
di: Robert J G Cardnell, et al.
Pubblicazione: (2011-01-01)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
di: Fallahi P, et al.
Pubblicazione: (2019-08-01)

N-Acetylcysteine Augments Surface Thiols and Differentially Modulates Cell Adhesion and Invasion in vitro and Metastatic Potential in vivo of B16F1 Melanoma
di: T. Laragione, et al.
Pubblicazione: (2005-01-01)

Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis
di: Busra Demirbag Gul, et al.
Pubblicazione: (2022-02-01)

LAMININ-5. A POTENTIAL TOOL IN DIAGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA
di: Hartwig Kosmehl, et al.
Pubblicazione: (2002-12-01)

Antitumor action of an aminochromene derivative on human - derived lung adenocarcinoma xenograft model
di: E. A. Samishina, et al.
Pubblicazione: (2019-06-01)

Transportan in nanocarriers improves skin localization and antitumor activity of paclitaxel
di: Pepe D, et al.
Pubblicazione: (2016-05-01)

Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply
di: Jr, W, et al.
Pubblicazione: (2012)

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
di: Carlos M. Galmarini, et al.
Pubblicazione: (2014-01-01)